Patents by Inventor Edmund Idris Graziani

Edmund Idris Graziani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SITE SPECIFIC HER2 ANTIBODY DRUG CONJUGATES
    Publication number: 20200377615
    Abstract: The present invention provides site specific HER2 antibody drug conjugates and methods for preparing and using the same.
    Type: Application
    Filed: June 3, 2020
    Publication date: December 3, 2020
    Applicant: Pfizer Inc.
    Inventors: Dangshe MA, Frank LOGANZO, Jr., Kimberly Ann MARQUETTE, Edmund Idris GRAZIANI, Puja SAPRA, Pavel STROP
  • Site specific HER2 antibody drug conjugates
    Patent number: 10689458
    Abstract: The present invention provides site specific HER2 antibody drug conjugates and methods for preparing and using the same.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: June 23, 2020
    Assignee: Pfizer Inc.
    Inventors: Dangshe Ma, Frank Loganzo, Jr., Kimberly Ann Marquette, Edmund Idris Graziani, Puja Sapra, Pavel Strop
  • ANTIBODIES AND ANTIBODY FRAGMENTS FOR SITE-SPECIFIC CONJUGATION
    Publication number: 20200069764
    Abstract: The invention relates to polypeptides, antibodies, and antigen-binding fragments thereof, that comprise a substituted cysteine for site-specific conjugation.
    Type: Application
    Filed: November 19, 2019
    Publication date: March 5, 2020
    Applicant: Pfizer Inc.
    Inventors: Dangshe MA, Kimberly Ann MARQUETTE, Edmund Idris GRAZIANI, Puja SAPRA, Lawrence Nathan TUMEY, Nadira Anarkali PRASHAD, Kiran Manohar KHANDKE, Eric M. BENNETT, Lioudmila TCHISTIAKOVA
  • ANTIBODIES AND ANTIBODY FRAGMENTS FOR SITE-SPECIFIC CONJUGATION
    Publication number: 20170216452
    Abstract: The invention relates to polypeptides, antibodies, and antigen-binding fragments thereof, that comprise a substituted cysteine for site-specific conjugation.
    Type: Application
    Filed: November 21, 2016
    Publication date: August 3, 2017
    Inventors: Dangshe MA, Kimberly Ann MARQUETTE, Edmund Idris GRAZIANI, Puja SAPRA, Lawrence Nathan TUMEY, Nadira Anarkali PRASHAD, Kiran Manohar KHANDKE, Eric M. BENNETT, Lioudmila TCHISTIAKOVA
  • SITE SPECIFIC HER2 ANTIBODY DRUG CONJUGATES
    Publication number: 20170151341
    Abstract: The present invention provides site specific HER2 antibody drug conjugates and methods for preparing and using the same.
    Type: Application
    Filed: November 21, 2016
    Publication date: June 1, 2017
    Applicant: Pfizer Inc.
    Inventors: Dangshe MA, Frank LOGANZO, JR., Kimberly Ann MARQUETTE, Edmund Idris GRAZIANI, Puja SAPRA, Pavel STROP
  • Cytotoxic peptides and antibody drug conjugates thereof
    Patent number: 9249186
    Abstract: The present invention is directed to cytotoxic pentapeptides, to antibody drug conjugates thereof, and to methods for using the same to treat cancer.
    Type: Grant
    Filed: July 8, 2015
    Date of Patent: February 2, 2016
    Assignee: Pfizer Inc.
    Inventors: Matthew David Doroski, Andreas Maderna, Christopher John O'Donnell, Chakrapani Subramanyam, Beth Vetelino, Russell George Dushin, Pavel Strop, Edmund Idris Graziani
  • CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF
    Publication number: 20150307551
    Abstract: The present invention is directed to cytotoxic pentapeptides, to antibody drug conjugates thereof, and to methods for using the same to treat cancer.
    Type: Application
    Filed: July 8, 2015
    Publication date: October 29, 2015
    Inventors: Matthew David DOROSKI, Andreas MADERNA, Christopher John O'DONNELL, Chakrapani SUBRAMANYAM, Beth VETELINO, Russell George DUSHIN, Pavel STROP, Edmund Idris GRAZIANI
  • Cytotoxic peptides and antibody drug conjugates thereof
    Patent number: 9138486
    Abstract: The present invention is directed to cytotoxic pentapeptides, to antibody drug conjugates thereof, and to methods for using the same to treat cancer.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: September 22, 2015
    Assignee: Pfizer Inc.
    Inventors: Matthew David Doroski, Andreas Maderna, Christopher John O'Donnell, Chakrapani Subramanyam, Beth Vetelino, Russell George Dushin, Pavel Strop, Edmund Idris Graziani
  • CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF
    Publication number: 20140363452
    Abstract: The present invention is directed to cytotoxic pentapeptides, to antibody drug conjugates thereof, and to methods for using the same to treat cancer.
    Type: Application
    Filed: July 2, 2014
    Publication date: December 11, 2014
    Inventors: Matthew David DOROSKI, Andreas MADERNA, Christopher John O'DONNELL, Chakrapani SUBRAMANYAM, Beth VETELINO, Russell George DUSHIN, Pavel STROP, Edmund Idris GRAZIANI
  • Cytotoxic peptides and antibody drug conjugates thereof
    Patent number: 8828401
    Abstract: The present invention is directed to cytotoxic pentapeptides, to antibody drug conjugates thereof, and to methods for using the same to treat cancer.
    Type: Grant
    Filed: November 7, 2012
    Date of Patent: September 9, 2014
    Assignee: Pfizer Inc.
    Inventors: Matthew David Doroski, Andreas Maderna, Christopher John O'Donnell, Chakrapani Subramanyam, Beth Vetelino, Russell George Dushin, Pavel Strop, Edmund Idris Graziani
  • Biosynthetic gene cluster for the production of a complex polyketide
    Patent number: 8030325
    Abstract: A polyketide synthase complex composed of polyketide synthase with 15 total modules, a non-ribosomal peptide synthetase with 1 module, and a cytochrome P450 hydroxylase is described. Also provided are novel Streptomyces species and methods of modified Streptomyces species. Further described are novel compounds, 36-ketomeridamycin, C9-deoxomeridamycin, and C9-deoxoprolylmeridamcyin and uses thereof.
    Type: Grant
    Filed: July 25, 2008
    Date of Patent: October 4, 2011
    Assignee: Wyeth LLC
    Inventors: Min He, John Hucul, Bradley Arnold Haltli, Melissa M. Wagenaar, Edmund Idris Graziani, Mia Summers, Kerry Kulowski, Kevin Pong, Xidong Feng
  • MACROLIDES AND METHODS FOR PRODUCING SAME
    Publication number: 20110144176
    Abstract: This invention relates, in part, to macrolide compounds, actinomycete strains for producing them, and pharmaceutical compositions containing them.
    Type: Application
    Filed: December 15, 2010
    Publication date: June 16, 2011
    Applicant: Wyeth LLC
    Inventors: Mia Haruna Yoshino SUMMERS, Edmund Idris Graziani, Margaret M. Leighton, Kevin Pong, Roger Alan Kele, David P. Labeda
  • Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders
    Patent number: 7795252
    Abstract: The present invention provides for methods of treating neurological disorders or complications due to stroke or head injury; benign or malignant neoplastic disease, carcinomas and adenocarcinomas; proliferative disorders; and inflammatory disorders using compounds of the following structure: The compounds are therefore useful as neuroprotective and neuroregenerative, anti-proliferative, and anti-inflammatory agents.
    Type: Grant
    Filed: June 9, 2009
    Date of Patent: September 14, 2010
    Assignee: Pfizer Inc.
    Inventors: Edmund Idris Graziani, Kevin Pong, Jerauld S. Skotnicki
  • Immunophilin Ligands and Methods for Modulating Immunophilin and Calcium Channel Activity
    Publication number: 20100196355
    Abstract: Immunophilin ligands and their uses as modulators of calcium channel activity are disclosed. Screening, therapeutic and prophylactic methods for conditions associated with calcium channel dysfunction, e.g., neurodegenerative and cardiovascular disorders, are also disclosed.
    Type: Application
    Filed: January 29, 2007
    Publication date: August 5, 2010
    Applicant: Wyeth
    Inventors: Edmund Idris Graziani, Benfang Helen Ruan, Kevin Pong, Mark Robert Bowlby
  • Meridamycin analogues for the treatment of neurodegenerative disorders
    Patent number: 7745457
    Abstract: A compound of the structure is described. This compound and its use for preparing medicines useful in the treatment of neurodegenerative disorders is described.
    Type: Grant
    Filed: March 5, 2007
    Date of Patent: June 29, 2010
    Assignee: Wyeth LLC
    Inventors: Edmund Idris Graziani, Kevin Pong
  • Rapamycin Analogues and the Uses Thereof in the Treatment of Neurological, Proliferative, and Inflammatory Disorders
    Publication number: 20090239855
    Abstract: The present invention provides for methods of treating neurological disorders or complications due to stroke or head injury; benign or malignant neoplastic disease, carcinomas and adenocarcinomas; proliferative disorders; and inflammatory disorders using compounds of the following structure: The compounds are therefore useful as neuroprotective and neuroregenerative, anti-proliferative, and anti-inflammatory agents.
    Type: Application
    Filed: June 9, 2009
    Publication date: September 24, 2009
    Applicant: Wyeth
    Inventors: Edmund Idris Graziani, Kevin Pong, Jerauld Skotnicki
  • Rapamycin Analogues and the Uses Thereof in the Treatment of Neurological Disorders
    Publication number: 20090203682
    Abstract: Method of treatment of neurological disorders or complications due to stroke or head injury through the administration of a pharmaceutical composition including a pharmaceutically acceptable excipient or carrier and a compound of formula I are provided:
    Type: Application
    Filed: November 24, 2008
    Publication date: August 13, 2009
    Applicant: Wyeth
    Inventors: Edmund Idris Graziani, Kevin Pong, Jerauld Skotnicki
  • Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders
    Patent number: 7560457
    Abstract: The present invention provides compounds of the following structure, wherein R1, R2, R4, R4?, R6, R7, and R15 are defined above: These compounds are useful in treating neurological disorders or complications due to stroke or head injury; benign or malignant neoplastic disease, carcinomas and adenocarcinomas; proliferative disorders; and inflammatory disorders. The compounds are therefore useful as neuroprotective and neuroregenerative, anti-proliferative, and anti-inflammatory agents.
    Type: Grant
    Filed: January 26, 2007
    Date of Patent: July 14, 2009
    Assignee: Wyeth
    Inventors: Edmund Idris Graziani, Kevin Pong, Jerauld Skotnicki
  • Biosynthetic Gene Cluster for the Production of a Complex Polyketide
    Publication number: 20090105294
    Abstract: A polyketide synthase complex composed of polyketide synthase with 15 total modules, a non-ribosomal peptide synthetase with 1 module, and a cytochrome P450 hydroxylase is described. Also provided are novel Streptomyces species and methods of modified Streptomyces species. Further described are novel compounds, 36-ketomeridamycin, C9-deoxomeridamycin, and C9-deoxoprolylmeridamcyin and uses thereof.
    Type: Application
    Filed: July 25, 2008
    Publication date: April 23, 2009
    Applicant: Wyeth
    Inventors: Min He, John Hucul, Bradley Arnold Haltli, Melissa M. Wagenaar, Edmund Idris Graziani, Mia Summers, Kerry Kulowski, Kevin Pong, Xidong Feng
  • Rapamycin Derivatives and the Uses Thereof in the Treatment of Neurological Disorders
    Publication number: 20090088448
    Abstract: Provided is a method of treating neurodegenerative disorders comprising administering to a subject in need thereof a compound of formula I:
    Type: Application
    Filed: December 5, 2008
    Publication date: April 2, 2009
    Applicant: Wyeth
    Inventors: Edmund Idris Graziani, Kevin Pong, Jerauld Skotnicki